Hims & Hers Health (NYSE:HIMS) Lowered to Hold Rating by Zacks Research

Key Points

• Hims & Hers Health has been downgraded from a "strong-buy" rating to a "hold" rating by Zacks Research, reflecting a shift in analyst sentiment.
• The company reported Q2 earnings with $544.83 million in revenue, falling short of analysts' expectations, and issued a quarterly EPS of $0.17, which missed estimates by $0.01.
• Insider trading activity showed CEO Andrew Dudum sold 660,000 shares for over $33 million, representing a significant decrease in his stake in the company.

Hims & Hers Health (NYSE:HIMS - Get Free Report) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a report issued on Tuesday,Zacks.com reports.

HIMS has been the topic of a number of other research reports. Truist Financial reduced their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a report on Monday, August 18th. Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Trading Up 1.3%

Shares of HIMS stock traded up $0.57 during mid-day trading on Tuesday, hitting $44.53. 27,930,748 shares of the company's stock were exchanged, compared to its average volume of 34,221,508. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock has a 50-day simple moving average of $51.71 and a two-hundred day simple moving average of $45.81. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock has a market cap of $10.06 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 3.01 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same quarter last year, the business earned $0.06 EPS. Hims & Hers Health's revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,107 shares of the business's stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the transaction, the chief financial officer owned 63,222 shares in the company, valued at $2,987,239.50. The trade was a 26.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the business's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,396,090 shares of company stock worth $71,927,627. Company insiders own 13.71% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Marex Group plc acquired a new position in shares of Hims & Hers Health in the second quarter worth about $53,626,000. Nomura Holdings Inc. increased its holdings in Hims & Hers Health by 151.4% in the second quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock valued at $8,028,000 after buying an additional 96,997 shares during the last quarter. Castleark Management LLC bought a new stake in Hims & Hers Health in the second quarter valued at about $2,921,000. Tower Research Capital LLC TRC increased its holdings in Hims & Hers Health by 54.3% in the second quarter. Tower Research Capital LLC TRC now owns 38,285 shares of the company's stock valued at $1,909,000 after buying an additional 13,473 shares during the last quarter. Finally, SkyView Investment Advisors LLC bought a new stake in Hims & Hers Health in the second quarter valued at about $226,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.